Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation
- PMID: 16609007
- DOI: 10.1158/1078-0432.CCR-05-2039
Delineation, functional validation, and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation
Abstract
A subset of follicular thyroid carcinomas contains a balanced translocation, t(2;3)(q13;p25), that results in fusion of the paired box gene 8 (PAX8) and peroxisome proliferator-activated receptor gamma (PPARG) genes with concomitant expression of a PAX8-PPARgamma fusion protein, PPFP. PPFP is thought to contribute to neoplasia through a mechanism in which it acts as a dominant-negative inhibitor of wild-type PPARgamma. To better understand this type of follicular carcinoma, we generated global gene expression profiles using DNA microarrays of a cohort of follicular carcinomas along with other common thyroid tumors and used the data to derive a gene expression profile characteristic of PPFP-positive tumors. Transient transfection assays using promoters of four genes whose expression was highly associated with the translocation showed that each can be activated by PPFP. PPFP had unique transcriptional activities when compared with PAX8 or PPARgamma, although it had the potential to function in ways qualitatively similar to PAX8 or PPARgamma depending on the promoter and cellular environment. Bioinformatics analyses revealed that genes with increased expression in PPFP-positive follicular carcinomas include known PPAR target genes; genes involved in fatty acid, amino acid, and carbohydrate metabolism; micro-RNA target genes; and genes on chromosome 3p. These results have implications for the neoplastic mechanism of these follicular carcinomas.
Similar articles
-
Genomic binding and regulation of gene expression by the thyroid carcinoma-associated PAX8-PPARG fusion protein.Oncotarget. 2015 Dec 1;6(38):40418-32. doi: 10.18632/oncotarget.6340. Oncotarget. 2015. PMID: 26595524 Free PMC article.
-
Genomic binding of PAX8-PPARG fusion protein regulates cancer-related pathways and alters the immune landscape of thyroid cancer.Oncotarget. 2017 Jan 24;8(4):5761-5773. doi: 10.18632/oncotarget.14050. Oncotarget. 2017. PMID: 28008156 Free PMC article.
-
Pioglitazone induces a proadipogenic antitumor response in mice with PAX8-PPARgamma fusion protein thyroid carcinoma.Endocrinology. 2011 Nov;152(11):4455-65. doi: 10.1210/en.2011-1178. Epub 2011 Sep 27. Endocrinology. 2011. PMID: 21952241 Free PMC article.
-
The role of the PAX8/PPARgamma fusion oncogene in the pathogenesis of follicular thyroid cancer.Mol Cell Endocrinol. 2010 May 28;321(1):50-6. doi: 10.1016/j.mce.2009.10.013. Epub 2009 Oct 31. Mol Cell Endocrinol. 2010. PMID: 19883731 Free PMC article. Review.
-
The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma.Curr Drug Targets Immune Endocr Metabol Disord. 2004 Sep;4(3):221-34. doi: 10.2174/1568008043339802. Curr Drug Targets Immune Endocr Metabol Disord. 2004. PMID: 15379724 Review.
Cited by
-
Genomic dissection of Hurthle cell carcinoma reveals a unique class of thyroid malignancy.J Clin Endocrinol Metab. 2013 May;98(5):E962-72. doi: 10.1210/jc.2012-3539. Epub 2013 Mar 29. J Clin Endocrinol Metab. 2013. PMID: 23543667 Free PMC article.
-
Thyrocyte-specific inactivation of p53 and Pten results in anaplastic thyroid carcinomas faithfully recapitulating human tumors.Oncotarget. 2011 Dec;2(12):1109-26. doi: 10.18632/oncotarget.380. Oncotarget. 2011. PMID: 22190384 Free PMC article.
-
Death-associated protein 3 is overexpressed in human thyroid oncocytic tumours.Br J Cancer. 2009 Jul 7;101(1):132-8. doi: 10.1038/sj.bjc.6605111. Epub 2009 Jun 16. Br J Cancer. 2009. PMID: 19536094 Free PMC article.
-
Retinoid X receptor γ regulates epithelial-mesenchymal transition and tumor immune infiltration in papillary thyroid cancer tumorigenesis: an experimental and in silico study.Endocr Connect. 2025 Jun 17;14(6):e250015. doi: 10.1530/EC-25-0015. Print 2025 Jun 1. Endocr Connect. 2025. PMID: 40465540 Free PMC article.
-
Evaluation of the Mammalian Aquaporin Inhibitors Auphen and Z433927330 in Treating Breast Cancer.Cancers (Basel). 2024 Jul 30;16(15):2714. doi: 10.3390/cancers16152714. Cancers (Basel). 2024. PMID: 39123442 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases